Comparison of the efficacy of the treatment of MRSA pulmonary infection in ICU with linidazolamide, substitute corrine and vancomycin

Objective:To compare the efficacy of the treatment of the pulmonary infection of MRSA in ICU in the treatment of ICU.Methods:The subjects were 165 patients with MRSA pulmonary infection received from ICU between 2015 October 2015 to February 2017,randomly divided them into group A, group B and group C, 45 cases each group ,respectively treated with the treatment of linazolamide,teicoplanin and vancomycin. Comparison of three groups of patients with total effective rate, bacterial removal efficient and incidence of adverse reactions, and compared before and after treatment serum white blood cell count (WBC), tumor necrosis factor alpha (TNF alpha), calcitonin (PCT) and c-reactive protein (CRP) level. Results: The total effective rate of treatment and bacterial clearance in group A were significantly higher than those in group B and C(P<0.05), and there was no significant difference between group B and group C (P>0.05);After treatment, the levels of WBC and serum TNF- alpha, PCT and CRP in group A were significantly lower than those in group B and C (P<0.01), but there was no significant difference between group B and group C (P<0.05). There was no significant difference in adverse reactions between the three groups(P<0.05).Conclusion:Linazolamide treatment in ICU pulmonary infection of MRSA curative effect is better than that of their teicoplanin and vancomycin, cleared to MRSA more thoroughly, the lung inflammatory response and control effect is better, and incidence of adverse reactions, clinical can give preference to rina thiazole amine treatment